TABLE 2. Signs and symptoms and rash sites among all cisgender women with mpox (N = 769) — United States, May 11–November 7, 2022*.
| Characteristic | Presence or absence of signs or symptoms, no. (%)† |
No. missing (% of total sample) | ||
|---|---|---|---|---|
| Present | Absent | Unknown | ||
|
Sign or symptom
| ||||
| Rash |
376 (92.6) |
17 (4.2) |
13 (3.2) |
363 (47.2) |
| Headache |
182 (54.3) |
122 (36.4) |
31 (9.3) |
434 (56.4) |
| Malaise |
176 (53.5) |
115 (35.0) |
38 (11.6) |
440 (57.2) |
| Fever |
165 (48.5) |
139 (40.9) |
36 (10.6) |
429 (55.8) |
| Chills |
162 (49.2) |
135 (41.0) |
32 (9.7) |
440 (57.2) |
| Pruritis |
164 (56.8) |
91 (31.5) |
34 (11.8) |
480 (62.4) |
| Myalgia |
142 (45.1) |
142 (45.1) |
31 (9.8) |
454 (59.0) |
| Enlarged lymph nodes |
137 (41.8) |
153 (46.7) |
38 (11.6) |
441 (57.3) |
| Vomiting or nausea |
63 (24.3) |
161 (62.2) |
35 (13.5) |
510 (66.3) |
| Abdominal pain |
57 (19.2) |
198 (66.7) |
42 (14.1) |
472 (61.4) |
| Rectal pain |
39 (12.8) |
229 (74.8) |
38 (12.4) |
463 (60.2) |
| Tenesmus |
22 (8.5) |
199 (76.8) |
38 (14.7) |
510 (66.3) |
| Conjunctivitis |
14 (5.7) |
199 (80.2) |
35 (14.1) |
521 (67.8) |
| Pus or blood in stools |
12 (4.6) |
210 (80.5) |
39 (14.9) |
508 (66.1) |
| Rectal bleeding |
11 (3.7) |
246 (82.8) |
40 (13.5) |
472 (61.4) |
| Proctitis |
8 (3.3) |
185 (76.5) |
49 (20.3) |
527 (68.5) |
|
Rash site
§
| ||||
| Legs |
182 (48.4) |
NA | NA | NA |
| Arms |
178 (47.3) |
|||
| Trunk |
125 (33.2) |
|||
| Genitals |
137 (36.4) |
|||
| Face |
116 (30.9) |
|||
| Palms |
81 (21.5) |
|||
| Head |
79 (21.0) |
|||
| Hand |
73 (19.4) |
|||
| Neck |
54 (14.4) |
|||
| Mouth |
57 (15.2) |
|||
| Perianal |
53 (14.1) |
|||
| Soles |
44 (11.7) |
|||
| Other | 100 (26.6) | |||
Abbreviation: NA = not applicable.
* Data as of November 9, 2022.
† Percentages calculated using nonmissing data.
§ Percentages among the 376 cisgender women who reported experiencing rash.